3 pharmaceutical IPOs expected in 2022

Emcure Pharma

Emcure Pharmaceuticals is India’s 12th largest pharmaceutical company, with revenues in the therapeutic areas of gynecology, blood, and HIV antivirals. It controls 51.53 percent of the HIV market. She is involved in the development, manufacture and marketing of a wide range of pharmaceutical products in a variety of therapeutic areas around the world.

Emcure Pharmaceuticals has filed a DRHP with SEBI for an IPO between Rs.4500 Cr and Rs.5000 Cr. The IPO would be carried out by a new issue of shares worth Rs. 1,100 Cr and a sale offer by the promoters and shareholders present. A pre-IPO placement of up to Rs. 200 Cr is also being considered by the company. If the pre-IPO goes well, the size of the IPO will be reduced. The proceeds of the new offering will be used to repay debt and for other operations of the company.

VLCC Health

VLCC Health

According to market sources, VLCC Health Care Ltd, one of India’s leading beauty and wellness companies, has obtained approval from capital markets regulator Sebi to launch its IPO. VLCC Health Care, which was founded in 1989, is today a well-known provider of wellness and beauty services and products. Over the past three decades, the brand has grown into a household name as well as a leader in the wellness market. VLCC’s mission to “transform lives” has been achieved with consumers in over 12 countries.

Over the past 2 years of the Covid-19 outbreak, the company’s focus on service performance and customer engagement has helped it increase repeat customer sales. As a result, in the fiscal year ending March 2021, they reported profit of Rs 6.24 crore on sales of Rs 532.92 crore.

Skanray Technologies

Skanray Technologies

Skanray Technologies is another company that has filed a DRHP with SEBI worth over Rs 400 crore. A new issue of Rs. 400 crore and an offer to sell shares are included in the IPO. A pre-IPO placement, which involves a new issue and an offer to sell, is also being considered by the firm. The proceeds from the new issue will be used to support the company’s inorganic development goals, cash flow requirements, investments in the company’s subsidiaries and capital expenditures.

Skanray Technologies has a dominant presence in the medical device industry in India. The company mainly focuses on the development, design, manufacture and marketing of medical equipment. Skanray’s portfolio is quite diverse, with three main categories: Radiological Equipment, Critical Care Solutions and Respiratory Management Systems. The company has an efficient in-house R&D team which issued 49 trademarks, 27 patents and 11 design registrations by the end of 2020.